Common Asthma Medicine Reduces Need for COVID-19 Hospitalization: Oxford Study

Worker walks with a COVID-19 patient at Nurse Isabel Zendal hospital, Madrid, Spain, January 29, 2021. REUTERS / Sergio Pérez

Feb 9 (Reuters) – A commonly used asthma treatment could reduce the need to hospitalize COVID-19 patients if the drug is administered within seven days of symptoms, British researchers said on Tuesday.

Budesonide, sold under the brand name Pulmicort by AstraZeneca Plc and also used for treating smoker’s lung, reduced the time required for patients to recover from COVID-19 also when administered by inhaler, said the University of Oxford. (https://bit.ly/3q40g1W)

(Report of Pushkala Aripaka in Bengaluru; Edited in Spanish by Javier López de Lérida)

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.